Dosimetric Evaluation and Clinical Application of Radioactive Iodine-125 Brachytherapy Stent in the Treatment of Malignant Esophageal Obstruction

Zhe Ji1, Qianqian Yuan2, Lei Lin1, Chao Xing2, Xusheng Zhang2, Sen Yang2, Yuliang Jiang1, Haitao Sun1, Kaixian Zhang2* and Junjie Wang1*

1 Department of Radiation Oncology, Peking University Third Hospital, Beijing, China, 2 Department of Oncology, Tengzhou Central People's Hospital, Zaozhuang, China

Objective: To evaluate the dosimetric characteristics and the clinical application of radioactive iodine-125 brachytherapy stent (RIBS) in malignant esophageal obstruction.

Methods: The dose distribution of RIBS with different seed spacing, diameter and length was studied by treatment planning system (TPS) calculation, thermoluminescence dosimeter (TLD) measurement and Monte Carlo (MC) data fitting. And the data of esophageal cancer patients who were treated with this type of RIBS was analyzed retrospectively.

Results: Doses around the RIBS calculated by the TPS lay between those measured by the TLDs and those simulated by the MC, and the differences between the three methods were significant (p<0.05), the overall absolute dose differences among the three methods were small. Dose coverage at 1.5 cm from the center was comprehensive when the activity reached 0.6 mCi. Both the conformability and the uniformity of isodose lines produced by a seed spacing of 1.0 cm were superior to those produced by a seed spacing of 1.5 cm. The data of 50 patients treated with RIBS was analyzed. They were followed up until February 2020 when all of the patients died. The overall improvement rate of dysphagia after RIBS implant was 90%. Moderate and severe complications with an incidence of more than 10% were hematemesis (28%), pain (20%), and lung infection (10%). Stent restenosis occurred in 4 patients at a median interval of 108 days from the procedure. The overall incidence of fatal complications was 38% (including hematemesis, infection and asphyxia). The median survival time of patients with and without a history of radiotherapy were 3.4 months and 6 months, respectively, the difference of which was significant (p=0.021). No other factors affecting survival were identified. For patients with and without a history of radiotherapy, the incidences of fatal complications were 51.7% and 19%, respectively (p=0.019). No correlation between dose and stent restenosis was found.
INTRODUCTION

Esophageal cancer is common and accounts for 572,000 new cases and 505,000 deaths each year, ranking the 9th most common type and the 6th leading cause of death among all cancers (1). While esophageal cancer is managed mainly by surgery and chemoradiotherapy (2), it is often more important to manage the problem of obstruction among patients with severe dysphagia. However, not only is it difficult for these patients to tolerate surgery or chemoradiotherapy due to unfavorable factors, such as advanced age, poor general condition, low body mass index, and severe comorbidities, but symptoms of obstruction also cannot be rapidly alleviated because of the delayed response of tumor for chemoradiotherapy.

The application of metal stents in the treatment of malignant esophageal obstruction was first reported by Frimberger (3) in 1983. Owing to its accurate positioning and simple operation, this technique can quickly and effectively relieve symptoms of dysphagia as well as improve patients’ nutritional status and quality of life, making it a standard method in treating malignant esophageal obstruction (4).

As conventional esophageal stents expand the esophagus simply by mechanical forces, they demonstrate no therapeutic effect on tumors that have caused the stenosis. In addition, due to growth of the tumor or proliferation of the granulation tissue, approximately 30–40% patients experience restenosis after stent implant (5), compromising the long-term efficacy of the stent. This issue has been resolved with the use of radioactive iodine-125 brachytherapy stent (RIBS), which can expand the esophagus while simultaneously performing brachytherapy on the tumor, thereby achieving the dual purpose of relieving dysphagia as well as eliminating cancer (6, 7). A recent randomized study showed that RIBS can prolong patient survival more effectively than conventional stents (8).

At present, there are few studies on the dosimetry of RIBS. In addition, existing studies are inconsistent regarding methods on the bundling methods and the quantity of seeds and provided little information on the prescription dose. The purpose of this study was to evaluate the dosimetric characteristics and the clinical application of RIBS in treating malignant esophageal obstruction, thereby providing references for its clinical implementation.

MATERIALS AND METHODS

RIBS Dosimetric Study

Materials

Several materials were used in this study, including a covered self-expanding esophageal stent (Micro-Tech (Nanjing) Co., Ltd., Jiangsu Province, China), and iodine-125 (I-125) seeds, type 6711_1985, with an outer diameter of 0.8 ± 0.02 mm and a length of 4.5 ± 0.2 mm (Atomic High Technology Co., Ltd., Beijing, China). The seed had an outer shell of titanium, a half-life of 59.4 days, a dose-rate constant of 0.965 cGy/(h·U), and various activities of 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 mCi. The following materials were also used: Allura Xper FD20 (Philips, Amsterdam, Netherlands), a digital subtraction angiography (DSA) system; OLYMPUS GIF-H290 (Olympus Co., Ltd., Tokyo, Japan), a gastroscope; paraffin as an analytical purity (Tianjin Basifu Chemical Co., Ltd., Tianjin, China); Brilliant Big Bore (Philips, MA, USA), a CT simulator; and a treatment planning system (TPS) (Beijing Feitianzhaoye Technology Co., Ltd., Beijing, China). Dose calculations at different distances to the radioactive source in the TPS were based on the American Association of Physicists in Medicine (AAPM) TG43 report and its updated documents (9, 10) and on thermoluminescence dosimeters (TLDs) (Beijing Institute of Chemical Defense, Beijing, China). These dosimeters were made of TLD-200 (LiF: Mg, Cu, P) square chips (3.2 cm × 3.2 cm) with a measurement range of 10 µGy to 10 Gy and a detection limit of 0.1 µGy, and a TLD reader, Harshaw 3500 (Thermo Fisher Scientific, MA, USA).

Methods

Preparation of Different Specifications of RIBS (4 Specifications)

Specification 1: length = 8.0 cm, diameter = 2.0 cm, and seed spacing = 1.0 cm; Specification 2: length = 8.0 cm, diameter = 2.0 cm, and seed spacing = 1.5 cm; Specification 3: length = 8.0 cm, diameter = 1.3 cm, and seed spacing = 1.0 cm; Specification 4: length = 12.0 cm, diameter = 2.0 cm, and seed spacing = 1.0 cm. The delivery sheath was made of polyurethane (synthesized from polytetrahydrofuran ether glycol, 4,4′-diphenylmethane diisocyanate, and 1,4-butanediol; density = 1.19 g/cm3). The RIBS was subsequently created by bundling a conventional stent with the delivery sheath containing radioactive I-125 seeds (Figures 1A, B).

TPS Calculations

The RIBS was vertically fixed in a cylindrical Perspex phantom (thickness = 0.8 cm, diameter = 20 cm, and height = 20 cm) filled with solid paraffin melt. Once the paraffin was cooled and solidified, the phantom was scanned using computed tomography (CT) (window width = 300 HU, window level = 15 HU, and slice thickness = 5 mm) (Figures 1C, D), and images were exported to the TPS. Subsequently, with the center of the stent as the origin, cumulative doses at a distance of 1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm, 3.5 cm, 4.0 cm, and 5.0 cm from the origin were calculated at both 0° and 90°, the average of which was computed as the result.

Conclusion:

TPS calculations are suitable for clinical applications. RIBS can effectively alleviate obstructive symptoms for patients with malignant esophageal obstruction, but the incidence of fatal complications was high, care should be taken when choosing this treatment.

Keywords: radioactive iodine-125 seed, stent, esophageal cancer, dosimetry, efficacy
Scattering, Rayleigh scattering and pair production were
removed from the phantom and read out in the TLD reader
1 cm from the origin. After being irradiated for 24 h, TLDs
were placed at 1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm,
3.5 cm, 4.0 cm, and 5.0 cm from the origin were calculated
at both 0° and 90°, the average of which was computed as the result.

**Clinical Outcomes of RIBS in the Treatment of Esophageal Cancer**

**Patient Information**

We retrospectively analyzed the data of patients with malignant
esophageal obstruction treated with this type of RIBS from July
2014 to November 2019. The criteria of RIBS treatment were:
① Patient’s age ≥ 18 years; ② Diagnosis of esophageal cancer was
pathologically confirmed; ③ Patient experienced Grade 3–4
dysphagia according to the criteria proposed by the Cardiovascular
and Interventional Radiological Society of Europe (CIRSE) (14), which stated that Grade 0 = normal diet,
Grade 1 = soft food only, Grade 2 = semi-solids only, Grade 3 =
liquids only, and Grade 4 = complete dysphagia; ④ Patient could
tolerate surgery or chemoradiotherapy due to extensive
tumor growth, metastasis, or poor medical conditions; ⑤
Patient demonstrated clear consciousness as well as good
compliance and was cooperative with treatment; and ⑥ Patient
had a Karnofsky Performance Score (KPS) ≥ 60 and could
tolerate treatment. The exclusion criteria were: ① The upper
boundary of the lesion exceeded the seventh cervical vertebra;
② Patient had ulcerative esophageal cancer or esophageal fistula;
③ Patient suffered from Class II or higher bone marrow
suppression and/or coagulation dysfunction; and ④ Patient had
other contradictions such as severe cardiopulmonary
insufficiency and liver and kidney insufficiency.

**Treatment Methods**

**Preoperative Planning**

Prior to the implant, a 5 mm enhanced CT scan of the lesion in
all areas was acquired, and CT images were exported to the TPS
to contour the esophageal lesions. Subsequently, a preoperative
plan was created with various seed activities ranging between 0.4
and 0.8 mCi and prescriptions ranging between 60 and 80 Gy.
Seeds were ordered once the total number and the activity
were determined.

**Production of the I-125 Seed Stent**

A covered esophageal stent with a diameter of 1.8 cm or 2.0 cm
was selected according to the length and stenosis of the patient’s
esophageal lesions. Each layer of the stent was bundled with 5–6
seeds, and the layers were separated by 1.0 cm. Seed spacing
was set according to the preoperative plan to ensure that the
prescription was fulfilled. Once radioactive seeds were fixed on
the periphery of the stent, the internal stent was inserted into the
sten pusher catheter.
Stent Implant
The patient was placed in the lateral position, anesthetized at the oropharynx with lidocaine spray, and a bite block was placed in the mouth. Subsequently, after a radiographic guide wire and a catheter were inserted through the oral cavity, contrast agents were injected in the upper and lower ends of the lesion to display the extent and the degree of stenosis. The imaging guide wire was then replaced with a super-hard and super-long guide wire, while the catheter was removed. Next, a covered stent of the right size was selected according to the extent of the lesion and implanted together with the pusher along the super-hard wire. Once its position was verified using proximal positioning, the stent was released. It was required that the upper and lower ends of the inserted stent should exceed the lesion by at least 20 mm.

Postoperative Plan Verification
At 48–72 hours after stent implantation, a 5 mm CT scan was acquired for review. After images were sent to the TPS, the esophageal lesion was contoured, and seeds were identified in the system to calculate the actual dose delivered to the tumor target (D90; i.e., the dose received by 90% of the target volume).

Outcome Indicators
Primary outcome indicators of this study included relief of patients’ clinical symptoms and relevant complications. Complications were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (15), there were five grades, as follows: mild/grade 1 (no symptoms and no treatment required), moderate/grade 2 (symptoms present and treatment required), severe/grade 3 (symptoms not controlled by drugs, and instrumentation or invasive procedure required), life-threatening/grade 4 (emergency treatment required), and death/grade 5. Secondary outcome indicators included patients’ survival. Factors influencing patients’ complications and survival were also investigated.

Statistical Analysis
Data analysis was performed using the SPSS 20 statistical software (IBM, Armonk, New York, USA). Measurement data were expressed as mean ± standard deviation (X̄ ± s), while count data were expressed as absolute value and percentage (rate). Comparisons of means and rates were conducted via the t-test and the chi-square test, respectively. Patient’s survival was calculated using the Kaplan-Meier method. Univariate analysis was performed using the log-rank test. The hazard ratio was derived via Cox regression. P < 0.05 was considered statistically significant.

RESULTS
Dosimetric Results
TPS Method
The dose around the RIBS dropped rapidly with increasing distance from the origin. According to the TPS, for stents of various specifications, the average doses (Gy) at seven different locations from the origin (1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm, 3.5 cm, 4.0 cm, and 5.0 cm) were 112.3 ± 31.50, 68.0 ± 20.71, 42.5 ± 16.28, 26.8 ± 9.95, 18.4 ± 7.18, 12.7 ± 5.76, and 7.8 ± 4.95, respectively, the differences of which were statistically significant (P < 0.001).

It was also noted that the dose increased linearly with increasing seed activity. For the six seed activities (0.5 mCi, 0.6 mCi, 0.7 mCi, 0.8 mCi, 0.9 mCi, and 1.0 mCi) investigated in the study, the average doses (Gy) at different locations from the origin were 26.4 ± 24.99, 32.3 ± 30.01, 38.6 ± 35.81, 45.4 ± 41.69, 50.9 ± 46.06, and 57.8 ± 50.67, respectively, differences of which were statistically significant (P < 0.001). The average doses (Gy) at 1.5 cm from the origin were 76.8 ± 14.55, 93.0 ± 18.55, 109.5 ± 22.41, 126.8 ± 28.29, 141.3 ± 27.39, and 155.8 ± 30.23, respectively, for the different seed activities. The dose coverage at 1.5 cm from the origin was comprehensive when the seed activity reached 0.6 mCi.

In addition, it was suggested that both seed spacing and stent length demonstrated significant effects on the dosimetry. The dose of the RIBS with a seed spacing of 1.5 cm was lower than that of the RIBS with a seed spacing of 1.0 cm. For the four different specifications of RIBS (Specification 1, Specification 2, Specification 3, and Specification 4), the average doses (Gy) at different locations from the origin were 30.6 ± 28.63, 41.0 ± 41.55, 43.6 ± 40.31, and 52.3 ± 46.22, respectively, the differences of which were statistically significant (P < 0.001). In addition, for the RIBS with a seed spacing of 1.0 cm, it was found that both the conformability and the uniformity of its isodose lines were superior to those of the RIBS with the seed spacing of 1.5 cm, whereas the latter showed several dosimetric “cold spots” on the plan (Figure 2).

TLD Method
The trends of TLD measurements were consistent with that of the TPS calculations. According to TLD measurements, for stents of various specifications, the average doses at seven different locations from the origin (1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm, 3.5 cm, 4.0 cm, and 5.0 cm) were 112.3 ± 31.50, 68.0 ± 20.71, 42.5 ± 16.28, 26.8 ± 9.95, 18.4 ± 7.18, 12.7 ± 5.76, and 7.8 ± 4.95, respectively, the differences of which were statistically significant (P < 0.001). In addition, although the dose at 1.5 cm measured by the TLD was not significantly different to that calculated by the TPS (t = -0.807, P = 0.428), at all other locations, TLD measurements were significantly lower than TPS calculations (t = 5.588, 4.881, 4.051, 3.358, 3.205, and 3.245, respectively, and P < 0.001, < 0.001, < 0.001, = 0.003, = 0.004 and = 0.004, respectively) (Figure 3A).

For the 6 seed activities (0.5 mCi, 0.6 mCi, 0.7 mCi, 0.8 mCi, 0.9 mCi, and 1.0 mCi), the average doses (Gy) at different locations from the origin were 24.7 ± 24.38, 30.3 ± 29.48, 36.5 ± 34.97, 44.0 ± 41.26, 48.6 ± 45.60, and 55.8 ± 49.06, respectively, the differences of which were statistically significant (P < 0.001) (Figure 3B). Alternatively, the average doses (Gy) at 1.5 cm from the origin were 74.5 ± 17.16, 89.8 ± 20.60, 106.3 ± 23.67, 125.8 ± 24.10, 138.8 ± 28.91, and 149.3 ± 29.41, respectively. Similarly, TLD measurements were consistently lower than TPS calculations, and the differences were statistically significant (t = 3.802, 4.615, 6.914, 3.300, 5.243, and 2.640, respectively,
and P = 0.001, < 0.001, < 0.001, = 0.003, < 0.001, and = 0.014, respectively).

For the four different specifications of RIBS (Specification 1, Specification 2, Specification 3, and Specification 4), the average doses (Gy) at different locations from the origin were 28.2 ± 27.88, 39.1 ± 40.42, 41.8 ± 39.36, and 50.8 ± 45.62, respectively, the differences of which were statistically significant (P < 0.001). Again, all TLD measurements were significantly lower than the TPS calculations (t = 5.835, 4.782, 4.106, and 4.836, respectively, and P < 0.001).

**MC Method**

The trends of MC simulations were consistent with that of the TLD measurements and TPS calculations. For stents of various specifications, the average doses (Gy) at seven different locations from the origin (1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm, 3.5 cm, 4.0 cm, and 5.0 cm) were 119.5 ± 35.04, 69.9 ± 20.18, 43.9 ± 16.32, 28.3 ± 10.39, 19.6 ± 6.95, 13.4 ± 5.90, and 8.0 ± 5.24, respectively, the differences of which were statistically significant (P < 0.001).

Although the dose at 5.0 cm simulated by MC was not considerably different from that calculated by the TPS measurements, all of the other MC simulation results were significantly higher. When compared to the TLD measurements, MC simulations were consistently higher with significant differences.
(t = −1.904, P = 0.07), at all other locations, MC simulation results were significantly higher (t = −3.686, −3.347, −4.303, −3.800, −2.930, and −4.303, respectively, and P = 0.001, = 0.003, < 0.001, = 0.001, = 0.008, and < 0.001, respectively). When compared to the TLD measurements, the MC simulations were consistently higher with significant differences (t = −8.150, −6.970, −5.901, −5.584, −4.532, −5.274, and −4.303, respectively, and P = 0.001, = 0.003, < 0.001, = 0.001, = 0.008, and < 0.001, respectively). However, the absolute dose difference between the two groups was less than 5 Gy. While the dose deviations in the high-dose area (1.5 and 2 cm from the origin) were 3.7% and 5.9%, respectively, the maximum deviation was 11.7% at 3 cm from the origin.

**Clinical Results**

**Patient Information**

A total of 50 patients were included in this study. Patients included were either ineligible or unwilling to receive radiotherapy, while stents were urgently needed to relieve their symptoms. Detailed patient information is listed in Table 1.

**RIBS Implant**

The RIBS implants were successful in the first attempt for all patients. The average operation time was approximately 15 min. Information on RIBS and related doses is listed in Table 2. After the implantation, patients were administered with 250 ml of hot milk to help expand the stent.

**Obstruction Relief**

Dysphagia was significantly improved in 90% of patients (45/50) after RIBS implant. For the 33 patients who could only eat a full-liquid diet before the procedure, 15 cases could eat soft foods, 13 cases could eat semi-liquid foods, and five remained on a liquid diet after the procedure, indicating an overall improvement rate of 85%. Alternatively, for the 17 patients with complete dysphagia before the procedure, 6 cases could eat soft foods, 9

### Table 1

| General information | N (50 cases) | % |
|---------------------|-------------|---|
| Gender              |             |   |
| Male                | 33          | 66.0 |
| Female              | 17          | 34.0 |
| Age (years old)     | mean 71 (range, 52-88) | median 70 (60-90) |
| KPS                 |             |   |
| III                 | 17          | 34.0 |
| IV                  | 33          | 66.0 |
| Location of lesions |             |   |
| Upper-thoracic      | 12          | 24.0 |
| Middle-thoracic     | 27          | 54.0 |
| Lower-thoracic      | 7           | 14.0 |
| Anastomosis         | 4           | 8.0 |
| Disease type        |             |   |
| Initial treatment   | 19          | 38.0 |
| Recurrence after treatment | 24 | 48.0 |
| Progress after treatment | 7 | 14.0 |
| History of radiotherapy |         |   |
| No                  | 21          | 42.0 |
| Yes                 | 29          | 58.0 |
| Degree of obstruction |          |   |
| Liquid diet         | 33          | 66.0 |
| Complete obstruction | 17         | 34.0 |
| Albumin before treatment (g/L) | mean 35.1 (24.4-42.9) | |
| Hemoglobin before treatment (g/L) | mean 120.6 (87-201) | |
cases could eat semi-solids, and 2 cases could eat liquids after the operation, indicating an overall improvement rate of 100%.

Complications
The incidences of pain, foreign body sensation, cough, nausea and vomiting, asphyxia, hematemesis, perforation, stent displacement, restenosis, and fever/pneumonia were 80%, 14%, 28%, 8%, 6%, 28%, 6%, 4%, 8%, and 6%, respectively. Stent restenosis occurred in four patients at a median interval of 108 days (31–196 days) from the procedure. No incidence of seed loss was observed. Details of the complications are shown in Table 3. Out of all of the patients, 3 cases suffered from asphyxia, all of which were fatal; 14 cases from hematemesis, 11 of which were fatal; 3 cases from perforation, all of which were fatal (2 cases due to hematemesis and 1 case due to lung infection); and 8 cases from fever or lung infection, 5 of which were fatal (with 1 case accompanied by perforation). Therefore, the overall incidence of fatal complications was 38% (19/50). Moderate and severe complications with an incidence of more than 10% were hematemesis (28%), pain (20%), and lung infection (10%).

Prognosis and Influencing Factors
Patients were followed up until February 2020 when all 50 patients died. The median survival was 4.4 months (95% CI: 3.4–5.4 months), and the 6-month, 12-month, and 18-month survival rates were 34%, 12%, and 2%, respectively (Figure 4A). A total of 6 patients survived for over 12 months, the longest of whom lived another 19.3 months after the procedure. Causes of death are listed in Table 4. The median survival periods of new and relapsed/uncontrolled patients were 5 months (95% CI: 2.9–9.1 months) and 3.9 months (95% CI: 2.8–4.9 months), respectively. The 18-month survival rates of the two groups were 5.3% and 3.2%, respectively, the difference of which was insignificant (P = 0.163). Alternatively, for patients with and without a previous history of radiotherapy, the median survival periods were 3.4 months (95% CI 2.1–4.7 months) and 6 months (95% CI: 2.8–9.3 months), respectively. The 18-month survival rates of the two groups were 0% and 4.8%, respectively, which were significantly different (P = 0.021) (Figure 4B). Specific factors affecting patients’ survival are shown in Figure 5.

The incidences of fatal complications in new and relapsed/uncontrolled patients were 21.1% (4/19) and 48.4% (15/31), respectively, the difference of which was close to statistical significance (chi-squared = 3.736, P = 0.053). Alternatively, for patients with and without a previous history of radiotherapy, the incidences of fatal complications were 51.7% (15/29) and 19% (4/21), respectively, the difference of which was significant (chi-squared = 5.520, P = 0.019). More specifically, for patients whose interval between radiotherapy and stent implant was < 6 months or ≥ 6 months, the incidences of upper gastrointestinal bleeding were 62.5% (5/8) and 14.3% (8/59), respectively, the difference of which was significant (chi-squared = 6.741, P = 0.019).

No correlation was found between dose and survival. For patients whose D90 ≤ 50Gy or > 50 Gy were 18.8% (3/16) and 47.1% (16/34), respectively, the difference of which was close to statistical significance (chi-squared = 3.701, P = 0.054). Similarly, no correlation between dose and stent restenosis was found. However, all stent restenosis occurred in patients receiving ≤ 66 Gy. The incidences of stent restenosis of patients receiving ≤ 66 Gy or > 66 Gy were 14.3% (5/35) and 0% (0/15), respectively (chi-squared = 2.381, P = 0.123).

| Complications                  | N   | %   |
|-------------------------------|-----|-----|
| Pain                          |     |     |
| No                            | 10  | 20  |
| Mild                          | 30  | 60  |
| Moderate                      | 7   | 14  |
| Severe                        | 3   | 6   |
| Foreign body feeling          |     |     |
| None                          | 43  | 86  |
| Mild                          | 6   | 12  |
| Moderate                      | 1   | 2   |
| Cough                         |     |     |
| None                          | 36  | 72  |
| Mild                          | 11  | 22  |
| Moderate                      | 2   | 4   |
| Severe                        | 1   | 2   |
| Nausea and vomiting           |     |     |
| None                          | 46  | 92  |
| Mild                          | 1   | 2   |
| Moderate                      | 3   | 6   |
| Asphyxia                      |     |     |
| None                          | 47  | 94  |
| Death                         | 3   | 6   |
| Haematemesis                  |     |     |
| None                          | 36  | 72  |
| Moderate                      | 3   | 6   |
| Death (with 2 cases of perforation) | 11  | 22  |
| Perforation                   |     |     |
| None                          | 47  | 94  |
| Death                         | 3   | 6   |
| Stent displacement            |     |     |
| No                            | 48  | 96  |
| Yes                           | 2   | 4   |
| Restenosis                    |     |     |
| No                            | 46  | 92  |
| Yes                           | 4   | 8   |
| Fever/pulmonary infection     |     |     |
| None                          | 42  | 84  |
| Mild/Moderate                 | 3   | 6   |
| Death (with 1 case of perforation) | 5   | 10  |

**TABLE 2 | RIBS parameters.**

| Parameters                    | Median (range) |
|-------------------------------|----------------|
| Length of stent (cm)          | 10 (6–12)      |
| Diameter of stent (cm)        | 2 (1.8–2)      |
| Seed spacing (cm)             | 1              |
| Number of seeds per layer     | 6 (5–8)        |
| Number of layers of seeds     | 5 (2–8)        |
| Seeds activity (mCi)          | 0.6 (0.4–0.8)  |
| Postoperative D90 (Gy)        | 56.7 (18.9–113.3) |

**TABLE 3 | Patients’ complications.**
DISCUSSIONS

Clarifying the dose distribution characteristics of RIBS and differences in doses calculated/measured by various methods can guide the clinical application of RIBS more effectively. As early as 1995, the AAPM TG-43 report established detailed I-125 dosimetry parameters and proposed evaluating methods for the dosimetry parameters of radioactive sources (9). As a random sampling statistical method, MC can simulate the transport of each incident particle in human tissue and, on this basis, calculate the three-dimensional dose deposition after irradiation with an accuracy close to that of reality (16). MC simulation has been widely applied to studies on radioactive source dosimetry owing to its ability to accurately model the physical process of radiotherapy (17–19).

In this study, dose distributions of different RIBSs were determined by a combination of TPS calculations, TLD measurements, and MC simulations. Despite the statistical differences among the three methods, the absolute dose difference was small (< 5 Gy), which was likely because of the large sample size (4 different specifications of stents and 6 seed activities) and a consistent trend. Values calculated by the TPS lay in the middle of the three methods (higher than TLD measurements but lower than MC simulations) and were less

| Cause of death                        | N  | %  |
|--------------------------------------|----|----|
| Tumor progression/cachexia            | 27 | 54 |
| Hemorrhage of upper digestive tract  | 11 | 22 |
| Infection                            | 5  | 10 |
| Asphyxia                             | 3  | 6  |
| Heart failure                        | 1  | 2  |
| Unknown reason                       | 3  | 6  |

TABLE 4 | Causes of death.

FIGURE 4 | (A) The overall 6-month, 12-month, and 18-month survival rates of all patients were 34%, 12%, and 2%, respectively. (B) For patients with and without a previous history of radiotherapy, the median survival periods were 3.4 months (95% CI: 1.1–4.7 months) and 6 months (95% CI: 2.8–9.3 months), respectively, and the 18-month survival rates were 0% and 4.8%, respectively. The difference of the latter was statistically significant (P = 0.021).

FIGURE 5 | Forest plot of factors affecting patients’ survival. While a previous history of radiotherapy led to the prognosis of patients (P = 0.021), no other influencing factors were identified (P > 0.05).
than 5% different from to those simulated by MC. In contrast, TLD measurements demonstrated the largest deviation (a maximum of 11.7%), which was predominantly caused by the superposition of doses from multiple radioactive seeds and the rapid dose fall-off around the RIBS. In general, TPS calculations showed good clinical accuracy and an acceptable dose deviation. When analyzing the effects of the length, diameter, and seed spacing of the stent on dose distribution, stent length and seed spacing was seen to exert substantial effects on the dose. More specifically, the longer the stent, the higher the dose, which was again caused by superposition of doses from multiple radioactive seeds. In addition, as the isodose lines produced by a seed spacing of 1.0 cm had better conformability and uniformity, in clinical practice, it was preferred to arrange the seeds at an interval of 1.0 cm. The recommended seed activity of a single I-125 seed for the treatment of esophageal cancer was 0.4–0.8 mCi based on in vitro and in vivo experiments (20). In our study, TPS isodose lines showed multiple cold spots when the activity was in the range of 0.4–0.5 mCi, whereas higher activities could lead to an increased risk of radiotoxicity. Therefore, most RIBS treatment was performed at a seed activity of 0.6 mCi in clinical practice.

Studies have shown vastly different therapeutic effects of RIBS in treating esophageal cancer, with the median survival ranging from 4 to 11 months. On the contrary, reports on the survival of patients treated with conventional stents are more consistent, ranging from 3 to 5 months (7, 8, 21-23). In terms of the relief of dysphagia and the incidence of complications, the performance of seed stents is similar to that of conventional stents (P > 0.05) (8, 24). In a randomized controlled study conducted by Zhu et al. (8) that included 148 patients (73 in the RIBS group and 75 in the conventional stent group), incidences of common complications, including severe chest pain (23% versus 20%), fistula (6% versus 7%), pneumonia (15% versus 19%), bleeding (7% versus 7%), and recurrence of dysphagia (28% versus 27%), were not significantly different. In our study, patients’ survival was relatively short (median survival was 4.4 months). Among all complications, the incidence of moderate to severe pain (20%), perforation (6%), and pneumonia (10%) was of a similar level, while that of bleeding was high (28%). The poor survival and the high incidence of fatal complications observed in this study were related to the fact that most patients were either relapsed/uncontrolled patients (62%) or had previously received radiotherapy (58%). In particular, patients with a previous history of radiotherapy showed low survival rates and high incidences of fatal complications. In addition, differences were statistically significant when compared these patients with those of patients without a history of radiotherapy (P = 0.021 and 0.019, respectively). This finding is consistent in reports by Zhu and Liu (8, 23), who listed previous history of radiotherapy as a poor prognostic factor. Since the incidence of fatal complications was substantially higher in patients with a history of radiotherapy than in those without, it was considered that the poor survival of the study mainly originated from complications. In particular, gastrointestinal bleeding is a complication that requires particular attention in patients whose interval of stent and radiotherapy was less than 6 months. Although the prognosis of patients who relapse after radiotherapy is even poorer, due to extremely limited treatment options, whether stent implant should be performed requires a joint decision made by the physician, patient, and patient’s family after carefully weighing the pros and cons. This study observed a low incidence of restenosis (8%) compared to a rate of 12.3% and 13.8% reported in literatures adopting conventional stents (25, 26). This is likely because of the superior dose distribution created by the more reasonable seed arrangement in the RIBS, which plays an important role in the prevention and treatment of restenosis caused by tumor overgrowth or in-growth. Stent restenosis occurred at a median interval of 108 days (31–196 days) after RIBS implanted in our study, by comparison, the median time of restenosis of conventional metal stents was about 2-30 weeks, which was related to tumor overgrowth, stent migration, granulation hyperplasia, food bolus obstruction and so on (25, 27). This also suggests that RIBS could probably delay the occurrence of restenosis, but due to the small number of cases and large time span, further confirmation is needed. Despite the short survival of patients receiving RIBS treatment, in actual clinical practice, most patients who need stent implant are advanced or relapsed or are refractory patients who are no longer eligible for surgery or chemoradiotherapy and yet suffer from severe obstructive symptoms. Therefore, treatment should focus on relieving symptoms and improving the quality of life. For these patients, RIBS can extend their survival by 4.4 months and allow them to eat during this period, making it valuable for palliative care. However, the risk of complications associated with the technique should be fully described to patients and their families prior to the treatment.

Dosimetric analysis in this study did not discover any factors affecting patients’ survival or incidence of complications. Potential indicative factors included D90 ≤ 50 Gy or > 50 Gy, which resulted in respective incidences of fatal complications of 18.8% and 47.1% with a difference close to statistical significance (P = 0.054); and D90 ≤ 66 Gy or > 66 Gy, which resulted in incidences of 14.3% and 0% (P = 0.123) of stent restenosis, respectively. Since existing dose evaluation methods for RIBS are still not standardized, only D90 was adopted in this study. In addition, due to large patient heterogeneity and incomplete information on patients’ tumor conditions and previous radiation doses, subsequent prospective research with more appropriate indicators is required to further clarify the role of RIBS in the treatment of esophageal cancer.

The limitations of the study are as follows: ① The analysis of dosimetry was elementary, especially without considering the influence of tissue heterogeneity and esophageal cavity on dosimetry, and solutions should be developed in next research. ② Retrospective study, follow-up data may be inaccurate or bias; ③ Because the results of survival and morbidity were not prominent, the significance of dosimetric data analysis was limited; ④ Because most patients were advanced, recurrent and refractory tumors, with poor prognosis and short survival time, it was difficult to observe long-term efficacy and complications; ⑤ The study had a high incidence of complications, which may need to be further refined in terms of technology, methods and patient selection, so as to benefit patients more specifically.
CONCLUSION

Doses around the RIBS calculated by the TPS lay between those measured by the TLD and those simulated by the MC, indicating that the TPS calculations are suitable for clinical applications. In addition, the overall dose differences among the three methods were small. Dose distribution was affected by seed activity, seed spacing, and stent length. Most RIBS treatment in this study was carried out with a seed spacing of 1.0 cm and a seed activity of 0.6 mCi. The application of RIBS in treating severely obstructed patients with esophageal cancer can effectively alleviate obstructive symptoms, but with a relatively high incidence of fatal complications. Relevant research should further identify the people who can benefit from the RIBS and focus on how to improve the safety and effectiveness of RIBS in the treatment of esophageal cancer.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article-supplementary material. Further inquiries can be directed to the corresponding authors.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492
2. Bordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, Committee EG. Oesophageal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2016) 27(suppl 5):v50–7. doi: 10.1093/annonc/mdw329
3. Frimberger E. Expanding Spiral—a New Type of Prosthesis for the Palliative Treatment of Malignant Esophageal Stenoses. Endoscopy (1983) 15 Suppl 1:213–4. doi: 10.1055/s-2007-1021511
4. Varghese TK Jr, Hofstetter WL, Rizk NP, Low DE, Darling GE, Watson TJ, et al. The Society of Thoracic Surgeons Guidelines on the Diagnosis and Staging of Patients With Esophageal Cancer. Ann Thorac Surg (2013) 96 (1):346–56. doi: 10.1016/j.jathorac.2013.02.009
5. Homs MY, Siersma PD. Stents in the GI Tract. Expert Rev Med Devices (2007) 4(5):741–52. doi: 10.1586/17434440.4.5.741
6. Guo JH, Teng GJ, Zhu GY, He SC, Deng G, He J. Self-Expandable Stent Loaded With 125I Seeds: Feasibility and Safety in a Rabbit Model. Eur J Radiol (2007) 61(2):356–61. doi: 10.1016/j.ejrad.2006.10.003
7. Guo JH, Teng GJ, Zhu GY, He SC, Fang W, Deng G, et al. Self-Expandable Esophageal Stent Loaded With 125I Seeds: Initial Experience in Patients With Advanced Esophageal Cancer. Radiology (2008) 247(2):574–81. doi: 10.1148/ radiol.2472070999
8. Zhu H-D, Guo J-H, Mao A-W, Lv W-F, Ji J-S, Wang W-H, et al. Conventional Stents Versus Stents Loaded With 125Iodine Seeds for the Treatment of Unresectable Oesophageal Cancer: A Multicentre, Randomised Phase 3 Trial. Lancet Oncol (2014) 15(6):612–9. doi: 10.1016/S1470-2045(14)70313-7
9. Nath R, Anderson LL, Lluxton G, Weaver KA. Dosimetry of Interstitial Brachytherapy Sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys (1995) 22(2):209–34. doi: 10.1118/1.597458
10. Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM Task Group No. 43 Report: A Revised AAPM Protocol for Brachytherapy Dose Calculations. Med Phys (2004) 31(3):633–74. doi: 10.1118/1.1646040
11. Dolan J, Liu Z, Williamson JF. Monte Carlo and Experimental Dosimetry of an 125I Brachytherapy Seed. Med Phys (2006) 33(12):4675–84. doi: 10.1118/1.2388158
12. Taylor RE, Rogers DW. More Accurate Fitting of 125I and 103Pd Radial Dose Functions. Med Phys. (2008) 35(9):4242–50. doi: 10.1118/1.2965409
13. Taylor RE, Rogers DW. An Egsnrc Monte Carlo–Calculated Database of TG–43 Parameters. Med Phys (2008) 35(9):4228–41. doi: 10.1118/1.2965360
14. Sabharwal T, Morales JP, Irani FG, Adam A. Quality Improvement Guidelines for Placement of Esophageal Stents. Cardiovasc Intervent Radiol (2005) 28 (3):284–8. doi: 10.1007/s00270-004-0344-6
15. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (2017). Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0.pdf
16. Moutsatsos A, Pantelis E, Papagiannis P, Bartsal D. Experimental Determination of the Task Group–43 Dosimetric Parameters of the New I25S1plus (125I) Brachytherapy Source. Brachytherapy (2014) 13(6):618–26. doi: 10.1016/j;brachy.2014.07.001
17. Mesbahi A, Fix M, Allahverdi M, Grein E, Garaati H. Monte Carlo Calculation of Varian 2300C/D Linac Photon Beam Characteristics: A Comparison Between MCNP4C, GENTJ3 and Measurements. Appl Radiat Isotopes Including Data Instrumentation Methods Use Agric Industry Med (2005) 62 (3):469–77. doi: 10.1016/j.apradiso.2004.07.008
18. Sadeghi M, Hamed Hosseini S. Study of the Isoaid ADVANTAGE (125I) Brachytherapy Source Dosimetric Parameters Using Monte Carlo Simulation. Appl Radiat Isot (2010) 68(1):211–3. doi: 10.1016/j.apradiso.2009.08.007
19. Sadi P, Sadeghi M, Shirazi A, Tenreiro C. Dosimetric Parameters of the New Design (103)Pd Brachytherapy Source Based on Monte Carlo Study. Phys Med (2012) 28(1):13–8. doi: 10.1016/j.ejmp.2010.12.005
20. Lv J, Cao XF, Zhu B, Ji L, An HY. –(125)I Seed Implantation Brachytherapy for Esophageal Squamous Cell Carcinoma. World Chin J Digest (2010) 18 (29):3065–71. doi: 10.11169/wjcd.v18.i29.3065
21. Zhongmin W, Xunbo H, Jun C, Gang H, Kemin C, Yu L, et al. Intraluminal Radioactive Stent Compared With Covered Stent Alone for the Treatment of Malignant Esophageal Stricture. Cardiovasc Intervent Radiol (2012) 35 (2):351–8. doi: 10.1007/s00270-011-0146-6

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent was not provided because this is a retrospective study which only analyzed the data of previously treated patients retrospectively. The patient signed the informed consent form before stent implantation, but it did not involve the informed consent form for the study.

AUTHOR CONTRIBUTIONS

Conceptualization, JW and KZ. Methodology, ZJ and JW. Software, ZJ and QY. Validation, LL, CX, and XZ. Formal analysis, ZJ and QY. Investigation, SY and YJ. Resources, LL and HS. Data curation, LL, QY, CX, and XZ. Writing—original draft preparation, ZJ and QY. Writing—review and editing, JW and KZ. Visualization, ZJ. Supervision, JW. Project administration, JW and KZ. ZJ and QY contributed equally to this work, so they are listed as co-first authors. All authors contributed to the article and approved the submitted version.
22. Dai Z, Zhou D, Hu J, Zhang L, Lin Y, Zhang J, et al. Clinical Application of Iodine-Eluting Stent in Patients With Advanced Esophageal Cancer. *Oncol Lett* (2013) 6(3):713–8. doi: 10.3892/ol.2013.1466

23. Liu N, Liu S, Xiang C, Cong N, Wang B, Zhou B, et al. Radioactive Self-Expanding Stents Give Superior Palliation in Patients With Unresectable Cancer of the Esophagus But Should Be Used With Caution If They Have had Prior Radiotherapy. *Ann Thorac Surg* (2014) 98(2):521–6. doi: 10.1016/j.athoracsur.2014.04.012

24. Doosti-Irani A, Mansournia MA, Rahimi-Foroushani A, Haddad P, Holakouie-Naieni K. Complications of Stent Placement in Patients With Esophageal Cancer: A Systematic Review and Network Meta-Analysis. *PloS One* (2017) 12(10):e0184784. doi: 10.1371/journal.pone.0184784

25. Homs MY, Steyerberg EW, Kuipers EJ, van der Gaast A, Haringsma J, van Blankenstein M, et al. Causes and Treatment of Recurrent Dysphagia After Self-Expanding Metal Stent Placement for Palliation of Esophageal Carcinoma. *Endoscopy* (2004) 36(10):880–6. doi: 10.1055/s-2004-825855

26. Stewart DJ, Balamurugan R, Everitt NJ, Ravi K. Ten-Year Experience of Esophageal Self-Expanding Metal Stent Insertion at a Single Institution. *Dis Esophagus* (2013) 26(3):276–81. doi: 10.1111/j.1442-2050.2012.01364.x

27. Hirdes MM, Siersema PD, Houben MH, Weusten BL, Vleggaar FP. Stent-in-Stent Technique for Removal of Embedded Esophageal Self-Expanding Metal Stents. *Am J Gastroenterol* (2011) 106(2):286–93. doi: 10.1038/ajg.2010.394

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ji, Yuan, Lin, Xing, Zhang, Yang, Sun, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.